Poseida Therapeutics Inc

+0.15 (+1.31%)
Earnings Announcements

Poseida Therapeutics Reports Q3 2020 Results

Published: 11/12/2020 21:49 GMT
(PSTX) - Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020.
Poseida Therapeutics, Inc. - Qtrly Loss per Share $0.63.
Poseida Therapeutics, Inc. - As of September 30, 2020, Cash, Cash Equivalents and Marketable Securities Were $341.5 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.69

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.